精華製藥(002349.SZ)上半年淨利1.29億元經營性現金流改善
格隆匯8月22日丨精華製藥(002349.SZ)披露2019年半年度報告,報告期內公司實現營業收入6.37億元,同比增長3.24%;歸屬於上市公司股東的淨利潤1.29億元,同比增長1.11%;經營活動現金淨流入6649.74萬元,同比增長542.71%;基本每股收益0.1579元,加權平均淨資產收益率5.49%。
報告期末,公司總資產36.88億元,較上年度末增長8.48%;歸屬於上市公司股東的淨資產23.72億元,較上年度末增長3.93%。
2019年上半年,醫藥行業面臨着更為嚴格的監管環境和激烈的市場競爭,行業增速有所下降。醫保控費、兩票制、全國集中帶量採購等政策陸續實施,對傳統醫藥行業的市場格局帶來巨大沖擊。公司聚焦主業,繼續踐行“全面提升中藥產業競爭優勢,持續鞏固化學原料藥及中間體市場基礎,積極開創生物製藥新產品和新增長點,嘗試進軍醫療服務養老養生健康產業”的發展戰略。
報告期內,公司主動適應醫藥環境變化和政策調整,對營銷構架進行調整,大力推進學術推廣,加大終端開發力度,施行精細化管理,加強資金管控,強化質量控制。報告期內,公司實現營業收入6.37億元,同比增長3.24%,實現歸屬於上市公司股東的淨利潤1.28億元,同比增長1.11%,公司經營業績繼續保持穩定增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.